tariquidar has been researched along with sdz psc 833 in 7 studies
| Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) | Studies (sdz psc 833) | Trials (sdz psc 833) | Recent Studies (post-2010) (sdz psc 833) |
|---|---|---|---|---|---|
| 210 | 16 | 138 | 455 | 55 | 66 |
| Protein | Taxonomy | tariquidar (IC50) | sdz psc 833 (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.3969 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baltes, S; Fedrowitz, M; Gastens, AM; Kaever, V; Löscher, W; Potschka, H | 1 |
| Chiba, P; Ecker, GF; Jabeen, I; Pleban, K; Rinner, U | 1 |
| Bootle, D; Charlton, P; Dangerfield, W; Liddle, C; Mistry, P; Okiji, S; Plumb, JA; Stewart, AJ; Templeton, D | 1 |
| Cocker, HA; Kelland, LR; Pinkerton, CR; Pritchard-Jones, K; Tiffin, N | 1 |
| Bates, SF; Chen, C; Figg, WD; Fojo, T; Kang, M; Robey, R | 1 |
| Callaghan, R; Mellor, HR; Modok, S | 1 |
| Ambudkar, SV; Barnett, D; Bates, SE; Finley, EM; Fojo, T; Oldham, RK; Robey, RW; Shukla, S | 1 |
2 review(s) available for tariquidar and sdz psc 833
| Article | Year |
|---|---|
Reversal of multidrug resistance: lessons from clinical oncology.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Clinical Trials as Topic; Cyclosporins; Dibenzocycloheptenes; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms; Piperidines; Pyridines; Quinolines; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Technetium Tc 99m Sestamibi; Tissue Distribution; Tumor Cells, Cultured | 2002 |
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; Cyclosporins; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imidazoles; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Quinolines; RNA Interference | 2006 |
1 trial(s) available for tariquidar and sdz psc 833
| Article | Year |
|---|---|
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Biological Factors; Biological Transport; Cell Line; Cell Line, Tumor; Cyclosporins; Depsipeptides; Fluorescent Dyes; Fluorouracil; Humans; Insecta; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Prazosin; Quinolines; Rhodamine 123; Verapamil; Vinblastine | 2008 |
4 other study(ies) available for tariquidar and sdz psc 833
| Article | Year |
|---|---|
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Topics: Analysis of Variance; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Carbamazepine; Cell Line; Cyclosporine; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Gene Expression; Humans; Levetiracetam; Mice; Phenytoin; Piracetam; Transfection | 2007 |
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzophenones; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Ligands; Models, Molecular; Molecular Conformation; Propafenone; Quantitative Structure-Activity Relationship; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2012 |
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Topics: Acridines; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Binding, Competitive; Cell Division; Cyclosporins; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Isoquinolines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Quinolines; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Tritium; Xenograft Model Antitumor Assays | 2001 |
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cisplatin; Cyclosporins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Inhibitory Concentration 50; Piperidines; Pyridines; Quinolines; Razoxane; Rhabdomyosarcoma; RNA, Neoplasm; Staurosporine; Time Factors; Tumor Cells, Cultured; Vincristine | 2001 |